(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 90.72% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Esperion Therapeutics's revenue in 2024 is $116,334,000.On average, 5 Wall Street analysts forecast ESPR's revenue for 2024 to be $42,176,102,207, with the lowest ESPR revenue forecast at $32,199,170,670, and the highest ESPR revenue forecast at $58,706,120,134. On average, 4 Wall Street analysts forecast ESPR's revenue for 2025 to be $86,489,378,105, with the lowest ESPR revenue forecast at $65,453,141,759, and the highest ESPR revenue forecast at $131,424,431,091.
In 2026, ESPR is forecast to generate $154,481,257,923 in revenue, with the lowest revenue forecast at $85,153,852,733 and the highest revenue forecast at $189,147,921,362.